Iovance Biotherapeutics (IOVA) Analyst Estimates Annual - Discounting Cash Flows
Iovance Biotherapeutics, Inc.
IOVA (NASDAQ)

* (except for per share items) of USD
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
2020
12-31
Number of Analysts 3 3 7 11 10 11 10 19
Estimated Revenue
Low 1,120 1,040 1,002 491 402 160 1.79 27.6
Average 1,406 1,306 1,010 730 449 162 4.42 34.5
High 1,612 1,497 1,018 926 468 168 10.7 41.4
Estimated EBITDA
Low 224 208 200 98.2 80.5 32.1 0.36 -319
Average 281 261 202 146 89.8 32.5 0.88 -265
High 322 299 204 185 93.7 33.7 2.15 -212
Estimated EBIT
Low 224 208 200 98.2 80.5 32.1 0.36 -320
Average 281 261 202 146 89.8 32.5 0.88 -267
High 322 299 204 185 93.7 33.7 2.15 -213
Estimated Net Income
Low 226 186 79.6 -154 -314 -403 -548 -317
Average 307 253 97.7 -97.7 -262 -372 -538 -264
High 366 301 129 35.7 -166 -259 -528 -211
Estimated SGA Expenses
Low 21,026 19,524 18,800 9,212 7,554 3,008 33.6 414
Average 26,397 24,511 18,957 13,701 8,428 3,050 83.0 518
High 30,258 28,096 19,115 17,384 8,789 3,160 202 622
Estimated EPS
Low 0.780 0.641 0.275 -0.532 -1.084 -1.390 -1.891 -1.915
Average 1.060 0.872 0.373 -0.278 -0.801 -1.295 -1.871 -1.846
High 1.262 1.038 0.444 0.123 -0.574 -0.895 -1.821 -1.752
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us